Other
Net Change in Cash
Regeneron Pharmaceuticals Net Change in Cash decreased by 125.1% to -$153.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 125.3%, from $604.00M to -$153.10M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementCash Flow Statement
SectionOther
CategoryLiquidity
SignalHigher is better
VolatilityVolatile
First reportedQ1 2017
Last reportedQ1 2026Apr 29, 2026
How to read this metric
A positive change indicates net cash generation, while a negative change indicates cash consumption for the period.
Detailed definition
The total net increase or decrease in cash, cash equivalents, and restricted cash during the reporting period. It is the...
Peer comparison
A fundamental liquidity metric used to compare cash management efficiency across all public companies.
Metric ID:
net_change_in_cashHistorical Data
13 periods
| Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q1 '24 | Q2 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.36B | $461.10M | $49.40M | $96.20M | $809.40M | -$1.98B | -$128.00M | -$681.60M | $604.00M | -$1.08B | $497.50M | $610.60M | -$153.10M |
| QoQ Change | — | -66.1% | -89.3% | +94.7% | +741.4% | -344.5% | +93.5% | -432.5% | +188.6% | -278.4% | +146.2% | +22.7% | -125.1% |
| YoY Change | — | — | — | -92.9% | +75.5% | <-999% | -115.8% | +65.6% | +571.9% | -58.1% | — | — | -125.3% |
Range-$1.98B – $1.36B
CAGR-51.7%
Avg YoY Growth-473.2%
Median YoY Growth-75.5%
Net Change in Cash at Other Companies
Frequently Asked Questions
- What is Regeneron Pharmaceuticals's net change in cash?
- Regeneron Pharmaceuticals (REGN) reported net change in cash of -$153.10M in Q1 2026.
- How has Regeneron Pharmaceuticals's net change in cash changed year-over-year?
- Regeneron Pharmaceuticals's net change in cash decreased by 125.3% year-over-year, from $604.00M to -$153.10M.
- What does net change in cash mean?
- The total change in the company's cash position over the period.